BioMérieux

Demand for the BioFire FilmArray panels continued to drive sales in the firm's molecular biology business.

Areas like pharma and food and water testing could prove growth areas for the platform as instrument sales growth slows in the clinic microbiology space.

The company also said that net income for the first half of 2017 rose 18 percent year over year to €101 million from €85.7 million.

The platform received 510(k) clearance from the US Food and Drug Administration for the expanded identification of mycobacteria, Nocardia, and molds.

The Inhale project is assessing respiratory disease tests on Oxford Nanopore's MinIon and PCR platforms from Curetis and BioMérieux's BioFire Diagnostics.

BioMérieux's organic growth saw a 9 percent increase to €566.4 million from €512.3 million in Q2 2016.

The firm will encounter stiff competition, particularly from BioMérieux and Luminex, but there are untapped opportunities for adoption, according to industry analysts.

BioMérieux said that the FilmArray RP2 reduces sample-to-result time to 45 minutes from about one hour, and provides increased pathogen coverage and sensitivity.

The approach is based on a new approval of the BacT/ALERT Virtuo system and new indications for the firm's procalcitonin assay.

Presented this week at the ECCMID annual meeting, the method uses mass spec to detect alterations to bacteria lipopolysaccharides that confer resistance.

Pages

Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.

The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.

CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.

In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.